Kanabo Group (KNB) Competitors

GBX 1.70
0.00 (0.00%)
(As of 04/25/2024 ET)

KNB vs. TLY, INHC, SAR, STX, BELL, PRM, MXC, LLAI, SNG, and IMM

Should you be buying Kanabo Group stock or one of its competitors? The main competitors of Kanabo Group include Totally (TLY), Induction Healthcare Group (INHC), Sareum (SAR), Shield Therapeutics (STX), Belluscura (BELL), Proteome Sciences (PRM), Argent BioPharma (MXC), LungLife AI (LLAI), Synairgen (SNG), and ImmuPharma (IMM). These companies are all part of the "medical" sector.

Kanabo Group vs.

Kanabo Group (LON:KNB) and Totally (LON:TLY) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, community ranking, media sentiment, valuation, earnings, institutional ownership, analyst recommendations, risk and dividends.

In the previous week, Totally had 4 more articles in the media than Kanabo Group. MarketBeat recorded 4 mentions for Totally and 0 mentions for Kanabo Group. Totally's average media sentiment score of 0.30 beat Kanabo Group's score of 0.00 indicating that Totally is being referred to more favorably in the news media.

Company Overall Sentiment
Kanabo Group Neutral
Totally Neutral

Totally received 129 more outperform votes than Kanabo Group when rated by MarketBeat users.

CompanyUnderperformOutperform
Kanabo GroupN/AN/A
TotallyOutperform Votes
129
72.47%
Underperform Votes
49
27.53%

Totally has higher revenue and earnings than Kanabo Group.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Kanabo Group£1K10,751.31-£4.65M-£0.01-170.00
Totally£121.20M0.08£1.78MN/AN/A

Totally has a consensus target price of GBX 30, suggesting a potential upside of 512.24%. Given Totally's higher probable upside, analysts clearly believe Totally is more favorable than Kanabo Group.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Kanabo Group
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
N/A
Totally
0 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
3.00

3.7% of Kanabo Group shares are owned by institutional investors. Comparatively, 37.6% of Totally shares are owned by institutional investors. 34.3% of Kanabo Group shares are owned by company insiders. Comparatively, 12.4% of Totally shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Kanabo Group has a beta of 3.22, indicating that its stock price is 222% more volatile than the S&P 500. Comparatively, Totally has a beta of 0.55, indicating that its stock price is 45% less volatile than the S&P 500.

Kanabo Group has a net margin of 0.00% compared to Totally's net margin of -0.80%. Totally's return on equity of -2.72% beat Kanabo Group's return on equity.

Company Net Margins Return on Equity Return on Assets
Kanabo GroupN/A -29.56% -10.56%
Totally -0.80%-2.72%0.30%

Summary

Totally beats Kanabo Group on 10 of the 15 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding KNB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

KNB vs. The Competition

MetricKanabo GroupMedical Care Facilities IndustryMedical SectorLON Exchange
Market Cap£10.75M£447.71M£4.98B£1.45B
Dividend YieldN/A4.06%2.99%8.47%
P/E Ratio-170.00276.36234.361,791.37
Price / Sales10,751.3171,711.422,355.91344,177.24
Price / Cash1.8213.0247.2133.44
Price / Book0.572.144.602.51
Net Income-£4.65M£1.39M£103.03M£183.18M
7 Day Performance13.33%-0.20%-0.51%4.71%
1 Month Performance-8.11%-5.70%-6.00%9.01%
1 Year Performance-42.37%-11.36%8.90%17.80%

Kanabo Group Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
TLY
Totally
2.7008 of 5 stars
GBX 4.60
flat
GBX 30
+552.2%
-76.5%£9.04M£121.20M-515.001,668Gap Up
INHC
Induction Healthcare Group
0 of 5 stars
GBX 12.50
flat
N/A-50.6%£11.55M£11.82M-83.3383
SAR
Sareum
0.7391 of 5 stars
GBX 16.50
+3.1%
GBX 304
+1,742.4%
-70.7%£11.84M£47,204.00-330.005Gap Up
High Trading Volume
STX
Shield Therapeutics
0 of 5 stars
GBX 1.53
flat
N/A-83.6%£11.93M£7.40M-12.7127
BELL
Belluscura
0 of 5 stars
GBX 7.50
+3.4%
N/A-78.7%£12.33M£1.20M-125.0024Gap Up
High Trading Volume
PRM
Proteome Sciences
0 of 5 stars
GBX 3.30
+6.1%
N/A-26.3%£9.74M£7.75M418.0029Gap Down
MXC
Argent BioPharma
0 of 5 stars
GBX 22
flat
N/AN/A£9.65M£1.32M-13.25N/A
LLAI
LungLife AI
0 of 5 stars
GBX 31
-1.6%
N/A-39.2%£9.51M£98,566.00-172.2215
SNG
Synairgen
0 of 5 stars
GBX 6.29
-5.6%
N/A-41.1%£12.67M£79,000.00-125.8034News Coverage
Gap Up
IMM
ImmuPharma
0 of 5 stars
GBX 2.26
-9.2%
N/A-27.3%£9.41M£94,819.00-226.0013Gap Down

Related Companies and Tools

This page (LON:KNB) was last updated on 4/25/2024 by MarketBeat.com Staff

From Our Partners